Biotin and contribution to normal energy-yielding metabolism: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

Abstract

Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to biotin and contribution to normal energy-yielding metabolism. The Panel considers that biotin, the food constituent that is the subject of the health claim, is sufficiently characterised. Contribution to normal energy-yielding metabolism is a beneficial physiological effect. The Panel has previously assessed a claim on biotin and contribution to normal energy-yielding metabolism with a favourable outcome. The target population was the general population. The Panel considers that the role of biotin in contributing to normal energy-yielding metabolism applies to all ages, including infants and young children (from birth to three years). The Panel concludes that a cause and effect relationship has been established between the dietary intake of biotin and contribution to normal energy-yielding metabolism. The following wording reflects the scientific evidence: ‘Biotin contributes to normal energy-yielding metabolism.’ The target population is infants and young children up to three years of age.

© European Food Safety Authority, 2015

Keywords: biotin, vitamin B7, infants, children, energy-yielding metabolism, health claims

Requestor: Competent Authority of France following an application by Specialised Nutrition Europe (formerly IDACE)

Question number: EFSA-Q-2008-188

Correspondence: nda@efs.europa.eu

Acknowledgements: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts for the preparatory work on this scientific output.


ISSN: 1831-4732

© European Food Safety Authority, 2015

Reproduction is authorised provided the source is acknowledged.
Summary

Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to biotin and contribution to normal energy-yielding metabolism.

The scope of the application was proposed to fall under a health claim referring to children’s development and health.

The general approach of the NDA Panel for the evaluation of health claims applications is outlined in the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims.

The food constituent that is the subject of the health claim is biotin, which is an essential nutrient and can be measured in foods by established methods. The Panel considers that biotin is sufficiently characterised.

The claimed effect proposed by the applicant is ‘plays an important role in the energy metabolism of food’. The target population proposed by the applicant is infants and young children from birth to three years of age. The Panel considers that contribution to normal energy-yielding metabolism is a beneficial physiological effect.

The Panel has previously assessed a claim on biotin and contribution to normal energy-yielding metabolism with a favourable outcome. The target population was the general population. The Panel considered that biotin plays a functional role in energy-yielding metabolism. The Panel considers that the role of biotin in contributing to normal energy-yielding metabolism applies to all ages, including infants and young children (from birth to three years).

The Panel concludes that a cause and effect relationship has been established between the dietary intake of biotin and contribution to normal energy-yielding metabolism.

The Panel considers that the following wording reflects the scientific evidence: ‘Biotin contributes to normal energy-yielding metabolism.’

In order to bear the claim, follow-on formulae should comply with the criteria for the composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria for the composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria for the composition of these foods as laid down in Directive 2006/125/EC; and other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for the nutritional labelling of foods intended for infants and young children as laid down in Directive 2006/141/EC. The target population is infants and young children up to three years of age. No Tolerable Upper Intake Level has been established for biotin.
## Table of contents

Abstract ........................................................................................................................................... 1
Summary ........................................................................................................................................... 3
1. Introduction ................................................................................................................................... 5
   1.1. Background and Terms of Reference as provided by the requestor ................................. 5
   1.2. Interpretation of the Terms of Reference ........................................................................... 5
   1.3. Additional information ........................................................................................................ 5
2. Data and Methodologies .............................................................................................................. 5
   2.1. Data ....................................................................................................................................... 5
   2.1.1. Information provided by the applicant ............................................................................. 5
   2.1.2. Data provided by the applicant ........................................................................................ 6
   2.2. Methodologies ...................................................................................................................... 6
3. Assessment .................................................................................................................................... 6
   3.1. Characterisation of the food/constituent ............................................................................. 6
   3.2. Relevance of the claimed effect to human health ................................................................. 7
   3.3. Scientific substantiation of the claimed effect ..................................................................... 7
   3.4. Panel’s comments on the proposed wording ..................................................................... 7
   3.5. Conditions and restrictions of use ....................................................................................... 7
4. Conclusions ................................................................................................................................... 8
Documentation provided to EFSA .................................................................................................... 9
References ....................................................................................................................................... 9
1. Introduction

1.1. Background and Terms of Reference as provided by the requestor

Regulation (EC) No 1924/2006\(^1\) harmonises the provisions that relate to nutrition and health claims, and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of this Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease risk claims and claims referring to children’s development and health in a Community list of permitted claims.

According to Article 15 of this Regulation, an application for authorisation shall be submitted by the applicant to the national competent authority of a Member State, which will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).

1.2. Interpretation of the Terms of Reference

EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to: biotin and contribution to normal energy-yielding metabolism.

The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing of biotin, a positive assessment of its safety or a decision on whether biotin is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wording of the claim and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.

1.3. Additional information

A claim on biotin and contribution to normal energy-yielding metabolism has previously been assessed by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) with a favourable outcome (EFSA NDA Panel, 2009).

2. Data and Methodologies

2.1. Data

2.1.1. Information provided by the applicant

Food/constituent as stated by the applicant:

- According to the applicant, the food constituent for which the claim is made is vitamin B\(_7\) (biotin).

Health relationship as claimed by the applicant:

- According to the applicant, vitamin B\(_7\) plays an important role in the energy metabolism of food.

---

Wording of the health claim as proposed by the applicant:

- The applicant has proposed the following wording for the health claim: ‘Vitamin B7 (biotin) contributes to normal fat metabolism and energy production’. As equivalent alternative wordings, the applicant has also proposed: ‘Vitamin B7 (biotin) is needed to release energy from food’; ‘Vitamin B7 (biotin) is important for the fat metabolism’; and ‘Vitamin B7 (biotin) helps release energy from fats’.

Specific conditions of use as proposed by the applicant:

- The target population proposed by the applicant is infants and young children from birth to three years of age.
- According to the applicant, the quantities needed to achieve the claimed effect are as follows:
  - For follow-on formulae, the content of vitamin B7 should be within the range set in Directive 2006/141/EC.
  - For Foods for Special Medical Purpose for infants and young children, the content of vitamin B7 should be within the range set in Directive 1999/21/EC, unless that is contrary to the intended use of the product.
  - For processed cereal-based foods and baby foods and for the other foods intended for infants and young children, the content of vitamin B7 should reach at least 15% of the Nutrient Reference Values set in Directive 2006/141/EC, i.e. 15% of 10 µg (1.5 µg) per 100 g or 100 mL serving, as reconstituted.

2.1.2. Data provided by the applicant

The applicant provided a health claim application on biotin and contribution to normal energy-yielding metabolism pursuant to Article 14 of Regulation 1924/2006. The application was presented in a common and structured format as outlined in the scientific and technical guidance for the preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2011a).

As outlined in the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims (EFSA NDA Panel, 2011b), it is the responsibility of the applicant to provide the totality of the available evidence.

2.2. Methodologies

The general approach of the NDA Panel for the evaluation of health claims applications is outlined in the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims (EFSA NDA Panel, 2011b).

3. Assessment

3.1. Characterisation of the food/constituent

The food constituent that is the subject of the health claims is biotin, which is an essential nutrient and can be measured in foods by established methods.

Biotin occurs naturally in foods as free biotin and in protein-bound forms; there are eight stereoisomers, but the D(+)-biotin is the only naturally occurring isomer that plays a role in human metabolism, and currently the only form authorised for addition to foods (Annex II of Regulation (EC)
Biotin and contribution to normal energy-yielding metabolism


The Panel considers that the food constituent, biotin, which is the subject of the health claim, is sufficiently characterised.

3.2. Relevance of the claimed effect to human health

The claimed effect proposed by the applicant is ‘plays an important role in the energy metabolism of food’. The target population proposed by the applicant is infants and young children from birth to three years of age.

The Panel considers that contribution to normal energy-yielding metabolism is a beneficial physiological effect.

3.3. Scientific substantiation of the claimed effect

The Panel has previously assessed a claim on biotin and contribution to normal energy-yielding metabolism with a favourable outcome (EFSA NDA Panel, 2009). The target population was the general population.

The Panel considered that biotin plays a functional role in energy-yielding metabolism (EFSA NDA Panel, 2009).

The Panel considers that the role of biotin in contributing to normal energy-yielding metabolism applies to all ages, including infants and young children (from birth to three years).

The Panel concludes that a cause and effect relationship has been established between the dietary intake of biotin and contribution to normal energy-yielding metabolism.

3.4. Panel’s comments on the proposed wording

The Panel considers that the following wording reflects the scientific evidence: ‘Biotin contributes to normal energy-yielding metabolism.’

3.5. Conditions and restrictions of use

The Panel considers that in order to bear the claim:

- follow-on formulae should comply with the criteria for the composition of follow-on formulae as laid down in Directive 2006/141/EC;
- nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria for the composition of these foods as laid down in Directive 1999/21/EC;
- processed cereal-based foods for infants and young children should comply with the criteria for the composition of these foods as laid down in Directive 2006/125/EC;

---

other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for the nutritional labelling of foods intended for infants and young children as laid down in Directive 2006/141/EC.

Such amounts can be easily consumed as part of a balanced diet. The target population is infants and young children up to three years of age. No Tolerable Upper Intake Level has been established for biotin (SCF, 2001).

4. Conclusions

On the basis of the data presented, the Panel concludes that:

- The food constituent, biotin, which is the subject of the health claim, is sufficiently characterised.
- The claimed effect proposed by the applicant is 'plays an important role in the energy metabolism of food'. The target population proposed by the applicant is infants and young children from birth to three years of age. Contribution to normal energy-yielding metabolism is a beneficial physiological effect.
- A cause and effect relationship has been established between the consumption of the dietary intake of biotin and contribution to normal energy-yielding metabolism.
- The following wording reflects the scientific evidence: ‘Biotin contributes to normal energy-yielding metabolism.’
- In order to bear the claim, follow-on formulae should comply with the criteria for the composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria for the composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria for the composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for the nutritional labelling of foods intended for infants and young children as laid down in Directive 2006/141/EC. The target population is infants and young children up to three years of age. No Tolerable Upper Intake Level has been established for biotin (SCF, 2001).
**Documentation provided to EFSA**


2. This application was received by EFSA on 14 February 2008.

3. The scope of the application was proposed to fall under a health claim referring to children’s development and health.

4. On 26 March 2008, during the validation process of the application, EFSA sent a request to the applicant to provide missing information.

5. On 29 April 2015, EFSA received the missing information as submitted by the applicant.

6. The scientific evaluation procedure started on 3 June 2015.

7. During its meeting on 29 June 2015, the NDA Panel, having evaluated the data, adopted an opinion on the scientific substantiation of a health claim related to biotin and contribution to normal energy-yielding metabolism.

**References**

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009. Scientific Opinion on the substantiation of health claims related to biotin and energy-yielding metabolism (ID 114, 117), macronutrient metabolism (ID 113, 114, 117), maintenance of skin and mucous membranes (ID 115), maintenance of hair (ID 118, 2876) and function of the nervous system (ID 116) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2009;7(9):12

